

# Patient Prescription Request



Name: ..... Date of Birth: ..... Mobile Phone: .....

Dear Healthcare Professional,  
Please use PhilRx to process my WELLBUTRIN XL prescription.

## How PhilRx Works

- 1 Send Prescription to PhilRx**  
Include your patient's mobile number and send to eRx: **PhilRx** or fax to **888-975-0603**. If you do not want your patient's WELLBUTRIN XL to be substituted with a generic bupropion HCl, please write *DAW1, Brand Medically Necessary*. Attach ICD-10 codes and tried/failed meds to eScript (in "note to pharmacist" section) or faxed script
- 2 PhilRx Provides Patient Support**  
PhilRx handles your patient's prior authorizations through CoverMyMeds®
- 3 Patient Receives Prescriptions Through the Independent Pharmacy Network**  
Inform your patient to look for a text message to confirm delivery and securely handle copayment

## Contact PhilRx

Direct Phone Line for Prescribers: **855-652-7445**

Website: [phil.us](http://phil.us)



## INDICATION

WELLBUTRIN XL® (bupropion hydrochloride extended-release tablets) is indicated for the treatment of major depressive disorder (MDD), and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.

## IMPORTANT SAFETY INFORMATION

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

#### SUICIDALITY AND ANTIDEPRESSANT DRUGS:

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older.

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

Please see additional Important Safety Information on next page. [Click here](#) for full Prescribing Information for WELLBUTRIN XL including Boxed Warning regarding suicidal thoughts and behaviors.

## IMPORTANT SAFETY INFORMATION (cont)

### Contraindications

WELLBUTRIN XL is contraindicated in:

- patients with a seizure disorder
- patients with a current or prior diagnosis of bulimia or anorexia nervosa, due to a higher incidence of seizures
- patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
- patients taking other bupropion products, including Zyban patients taking a monoamine oxidase inhibitor (MAOI) or within 14 days of discontinuing MAOI treatment
- patients with hypersensitivity to bupropion or other ingredients of WELLBUTRIN XL

### Warnings and Precautions

- WELLBUTRIN XL is not approved for smoking cessation treatment; however, bupropion HCl sustained-release is approved for this use. Postmarketing reports of serious or clinically significant neuropsychiatric adverse events with smoking cessation treatment have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with WELLBUTRIN XL for the occurrence of such symptoms and instruct them to discontinue WELLBUTRIN XL and contact a healthcare provider if they experience such adverse events.
- Bupropion is associated with a dose-related risk of seizures. The dose should not exceed 300 mg once daily. Increase the dose gradually. Discontinue WELLBUTRIN XL and do not restart treatment if the patient experiences a seizure. Use with extreme caution in patients with a history of seizure or cranial trauma, or in patients treated with other medications that lower the seizure threshold.
- Treatment with WELLBUTRIN XL can result in elevated blood pressure and hypertension. Assess blood pressure before initiating treatment with WELLBUTRIN XL, and monitor periodically during treatment.
- Antidepressant treatment can precipitate a manic, mixed, or hypomanic manic episode. Prior to initiating WELLBUTRIN XL, screen patients for a history of bipolar disorder and the presence of risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression). WELLBUTRIN XL is not approved for the treatment of bipolar depression.
- Depressed patients treated with bupropion have had a variety of neuropsychiatric signs and symptoms, including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. Some of these patients had a diagnosis of bipolar disorder. In some cases, these symptoms abated upon dose reduction and/or withdrawal of treatment. Discontinue WELLBUTRIN XL if these reactions occur.

- The pupillary dilation that occurs following use of many antidepressant drugs including WELLBUTRIN XL may trigger an angle closure attack (Angle-Closure Glaucoma) in a patient with anatomically narrow angles who does not have a patent iridectomy.
- Anaphylactoid/anaphylactic reactions have occurred during clinical trials with bupropion, as well as rare, postmarketing reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with immediate-release bupropion.

### Adverse Reactions

- The most common adverse reactions that occurred in at least 5% of patients treated with bupropion HCl sustained-release (300 mg and 400 mg per day) and at a rate at least twice the placebo rate were: anorexia, dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, urinary frequency, and rash.

### Drug Interactions

- An increased dose of bupropion may be necessary if co-administered with CYP2B6 inducers based on clinical exposure but should not exceed the maximum recommended dose. Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics. Consider dose reduction when using with bupropion. Dose bupropion with caution when used with drugs that lower seizure threshold. CNS toxicity can occur when bupropion is used concomitantly with dopaminergic drugs.
- WELLBUTRIN XL can cause false-positive urine test results for amphetamines.

### Use in Special Populations

- **Pregnancy:** Use only if benefit outweighs potential risk to the fetus. Healthcare providers are encouraged to register patients in the Pregnancy Exposure Registry by calling 1-844-405-6185 or visiting <https://womensmentalhealth.org/research/pregnancyregistry/>.
- In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose is **150 mg every other day**. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6) or renal impairment (glomerular filtration rate <90 mL/min), consider reducing the dose and/or frequency of dosing.
- Advise patients to read the FDA-approved patient labeling (Medication Guide). Inform patients, their families, and their caregivers about the benefits and risks associated with treatment with WELLBUTRIN XL and counsel them in its appropriate use.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see additional Important Safety Information on prior page. [Click here](#) for full Prescribing Information for WELLBUTRIN XL including Boxed Warning regarding suicidal thoughts and behaviors.**

## BAUSCH Health

WELLBUTRIN XL is a registered trademark of GlaxoSmithKline LLC used under license.

CoverMyMeds is a registered trademark of CoverMyMeds LLC.

Any other product/brand names and/or logos are trademarks of the respective owners.

© 2022 Bausch Health Companies Inc. or its affiliates.

WXL.0051.USA.20 (v2.0)

